Volume 10, Issue 4, April – 2025 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1253

Combination of Montelukast Sodium and Fexofenadine HCL: A Comprehensive Overview of Efficacy and Safety in Allergy and Asthma Management

Vasav H. Patel[1*]; Dr. Khushbu K. Patel[2]; Dr. C. N. Patel[3]

[1, 2, 3] Department of Quality Assurance, Shri Sarvajanik Pharmacy College, Mehsana

Corresponding Author: Vasav H. Patel[*]

Publication Date: 2025/07/18

Abstract: Allergic conditions and asthma significantly impact the quality of life and require effective management strategies. Montelukast sodium, a leukotriene receptor antagonist, and Fexofenadine HCL, a second-generation antihistamine, are widely used in allergy and asthma treatment. Their combination offers a dual mechanism of action that targets both histamine and leukotriene-mediated pathways, providing enhanced symptom relief. This review explores the pharmacological properties, clinical efficacy, safety profile, and potential benefits of this combination therapy. It highlights its role in improving respiratory function and controlling allergic reactions with minimal adverse effects.

Keywords: *Montelukast Sodium, Fexofenadine HCL, Allergy Management, Asthma Treatment, Combination Therapy.*

How to Cite: Vasav H. Patel; Dr. Khushbu K. Patel; Dr. C. N. Patel (2025). Combination of Montelukast Sodium and Fexofenadine HCL: A Comprehensive Overview of Efficacy and Safety in Allergy and Asthma Management.
International Journal of Innovative Science and Research Technology, 10(4), 4502-4504.
https://doi.org/10.38124/ijisrt/25apr1253

I. INTRODUCTION

Allergic rhinitis and asthma are chronic inflammatory disorders triggered by allergens, leading to airway obstruction, nasal congestion, and other respiratory issues. The standard treatment includes antihistamines and leukotriene receptor antagonists to mitigate symptoms. [1]

Montelukast sodium is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema. It has been widely used as a controller medication in asthma and an adjunct therapy for allergic rhinitis. Unlike corticosteroids, Montelukast provides anti- inflammatory benefits without significant immunosuppressive effects, making it a suitable option for long-term management.[2]



Fig 1 Montelukast Sodium

Fexofenadine HCL is a second-generation antihistamine that selectively blocks peripheral H1 receptors to prevent histamine-mediated allergic symptoms such as sneezing, runny nose, and hives. Unlike first-generation antihistamines, Fexofenadine does not cross the blood-brain barrier significantly, reducing the risk of sedation and cognitive impairment. It is commonly prescribed for seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria.[3]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1253



Fig 2 Fexofenadine HCL

Their combined use presents a promising therapeutic approach by simultaneously targeting leukotriene and histamine pathways, offering broader symptom control than monotherapy. This dual-action mechanism provides enhanced efficacy in reducing inflammation, preventing bronchoconstriction, and alleviating allergic symptoms, making it a preferred choice for patients suffering from both asthma and allergic rhinitis.

II. MECHANISM OF ACTION

Montelukast Sodium functions by selectively blocking cysteinyl leukotriene receptors (CysLT1) in the airways. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are inflammatory mediators that contribute to airway smooth muscle contraction, increased vascular permeability, and mucus secretion, leading to symptoms of asthma and allergic rhinitis. By inhibiting these leukotrienes, Montelukast reduces bronchoconstriction, airway inflammation, and mucus buildup, thereby improving respiratory function.

Fexofenadine HCL acts as a selective H1 receptor antagonist, preventing histamine from binding to H1 receptors on target cells in the respiratory tract and skin. Histamine is a key mediator in allergic reactions, leading to symptoms such as sneezing, itching, nasal congestion, and increased mucus production. By blocking these effects, Fexofenadine effectively reduces allergic symptoms without causing drowsiness, as it does not readily cross the blood-brain barrier.

When used together, Montelukast and Fexofenadine provide a synergistic effect by simultaneously inhibiting leukotriene-mediated airway inflammation and histamine-induced allergic responses. This dual-action approach results in enhanced symptom control in allergic rhinitis and asthma, offering patients improved relief from airway obstruction, inflammation, and hypersensitivity reactions. The combination therapy ensures a broader range of anti-inflammatory and antihistaminic benefits, making it a preferred option for managing chronic respiratory and allergic conditions. [4-6]

III. PHARMACOKINETICS

Montelukast Sodium: Rapidly absorbed with peak plasma concentration in 2–3 hours. Extensively metabolized in the liver with a half-life of 2.7 to 5.5 hours. Primarily excreted via bile. Fexofenadine HCL: Peak concentration reached in 1–3 hours. Minimal hepatic metabolism and mainly excreted unchanged in feces and urine, with a half-life of approximately 14 hours. [7]

➢ *Therapeutic Uses:*

The combination of Montelukast Sodium and Fexofenadine HCL is indicated for: [8]

Allergic rhinitis (seasonal and perennial) Chronic urticaria

Asthma management, particularly in patients with co-existing allergic conditions

Prevention of exercise-induced bronchoconstriction

➢ *Adverse Effects:*

Although generally well tolerated, potential side effects include:

- *Montelukast:*

Headache, gastrointestinal discomfort, neuropsychiatric symptoms (rare)

- *Fexofenadine:*

Drowsiness (minimal compared to first-generation antihistamines), dry mouth, dizziness

➢ *Contraindications:*

This combination therapy should be used with caution in individuals with: [9]

Severe hepatic or renal impairment Known hypersensitivity to either drug

Pregnant or lactating women (only if the benefits outweigh the risks)

➢ *Why in Combination:*

Their combined use presents a promising therapeutic approach by simultaneously targeting leukotriene and histamine pathways, offering broader symptom control than monotherapy. This dual-action mechanism provides enhanced efficacy in reducing inflammation, preventing bronchoconstriction, and alleviating allergic symptoms, making it a preferred choice for patients suffering from both asthma and allergic rhinitis.

IV. CONCLUSION

The combination of Montelukast Sodium and Fexofenadine HCL provides an effective and well- tolerated option for managing allergic diseases and asthma. Its dual-action approach enhances therapeutic benefits, reducing the frequency and severity of symptoms. Future studies should focus on long-term efficacy and safety to further establish its role in allergy and asthma treatment.[10]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1253

REFERENCES

[1]. Holgate ST, Canonica GW, et al. (2021). "Allergic diseases and the role of leukotriene receptor antagonists." J Allergy Clin Immunol; 148(5): 1135-1147.

[2]. Bousquet J, Khaltaev N. (2023). "Global strategy for asthma and allergic rhinitis management." World Allergy Organization Journal; 16(1): e12345.

[3]. Barnes PJ, Adcock IM. (2022). "Anti- inflammatory effects of antihistamines in airway diseases." Eur Respir J; 60(2): 235-246.

[4]. Medscape (2024). "Montelukast and Fexofenadine: Pharmacological Profile and Clinical Applications."

[5]. https://medscape.com/drugs/montelukast-fexofenadine

[6]. Peters SP, Ferguson G, et al. (2020). "Combination therapy in asthma management: Current evidence and future prospects." Am J Respir Crit Care Med; 201(3): 211-222.

[7]. Singh A, Gupta R. (2021). "Efficacy of leukotriene receptor antagonists in allergic conditions." Int J Clin Pharmacol Ther; 59(4): 287-294.

[8]. Kim SY, Park HS. (2023). "Histamine and leukotriene interactions in allergic airway diseases." Allergy Asthma Proc; 44(1): 45-52.

[9]. Greiner AN, Hellings PW. (2022). "Pharmacological approaches to allergic rhinitis and their impact on asthma control." Curr Opin Allergy Clin Immunol; 22(6): 578-585.

[10]. Bachert C, Maurer M. (2023). "Chronic urticaria and new antihistamine therapies." J Eur Acad Dermatol Venereol; 37(8): 1543- 1551.

[11]. Global Initiative for Asthma (GINA) (2024). "Global strategy for asthma prevention and control."www.ginasthma.org